Anteris Technologies Global’s (AVR) “Overweight” Rating Reiterated at Cantor Fitzgerald

Anteris Technologies Global (NASDAQ:AVR)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $15.00 target price on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 135.11% from the stock’s current price.

Several other brokerages have also weighed in on AVR. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Barclays upgraded Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $14.00.

Anteris Technologies Global Stock Down 1.1%

AVR opened at $6.38 on Wednesday. The firm has a market cap of $621.79 million, a price-to-earnings ratio of -3.26 and a beta of 1.87. The company’s 50-day moving average price is $8.32 and its 200 day moving average price is $8.05. Anteris Technologies Global has a fifty-two week low of $3.30 and a fifty-two week high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%. The company had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.50 million. During the same quarter in the previous year, the company earned ($0.58) earnings per share. Research analysts anticipate that Anteris Technologies Global will post -1.21 earnings per share for the current year.

Insider Activity at Anteris Technologies Global

In other news, major shareholder L1 Capital Pty Ltd bought 648,455 shares of the business’s stock in a transaction on Monday, October 5th. The stock was purchased at an average price of $7.51 per share, with a total value of $4,869,897.05. Following the transaction, the insider directly owned 12,778,380 shares in the company, valued at approximately $95,965,633.80. The trade was a 5.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders bought 1,554,730 shares of company stock worth $11,694,513 and sold 3,008,459 shares worth $25,243,576. Corporate insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC raised its position in Anteris Technologies Global by 26,789.3% in the third quarter. Farther Finance Advisors LLC now owns 15,058 shares of the company’s stock worth $117,000 after purchasing an additional 15,002 shares in the last quarter. Nantahala Capital Management LLC acquired a new position in Anteris Technologies Global in the second quarter worth about $33,325,850. One68 Global Capital LLC acquired a new position in Anteris Technologies Global in the second quarter worth about $128,000. Bank of America Corp DE acquired a new position in Anteris Technologies Global in the second quarter worth about $1,907,000. Finally, AWM Investment Company Inc. acquired a new position in Anteris Technologies Global in the second quarter worth about $1,133,000.

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.